Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
38 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Actinium Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Actinium Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Actinium Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Actinium Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Actinium Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Actinium Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Actinium Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Actinium Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Actinium Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Actinium Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Actinium Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Actinium Pharmaceuticals, Inc. Snapshot 5 Actinium Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Actinium Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Actinium Pharmaceuticals, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Actinium Pharmaceuticals, Inc. - Pipeline Products Glance 11 Actinium Pharmaceuticals, Inc. - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Actinium Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Actinium Pharmaceuticals, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Actinium Pharmaceuticals, Inc. - Drug Profiles 15 Iomab-B 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 HuM195-Ac-225 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 AAA-225 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Actimab-B 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Actimab-Br 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Actimab-C 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Actimab-P 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Monoclonal Antibody Conjugate for Cancer 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Actinium Pharmaceuticals, Inc. - Pipeline Analysis 25 Actinium Pharmaceuticals, Inc. - Pipeline Products by Target 25 Actinium Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 26 Actinium Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 27 Actinium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 28 Actinium Pharmaceuticals, Inc. - Recent Pipeline Updates 29 Actinium Pharmaceuticals, Inc. - Dormant Projects 34 Actinium Pharmaceuticals, Inc. - Discontinued Pipeline Products 35 Discontinued Pipeline Product Profiles 35 Bismab-A 35 Actinium Pharmaceuticals, Inc. - Locations And Subsidiaries 36 Head Office 36 Appendix 37 Methodology 37 Coverage 37 Secondary Research 37 Primary Research 37 Expert Panel Validation 37 Contact Us 38 Disclaimer 38
List of Tables Actinium Pharmaceuticals, Inc., Key Information 5 Actinium Pharmaceuticals, Inc., Key Facts 5 Actinium Pharmaceuticals, Inc. - Pipeline by Indication, 2014 8 Actinium Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 9 Actinium Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 10 Actinium Pharmaceuticals, Inc. - Phase III, 2014 11 Actinium Pharmaceuticals, Inc. - Phase II, 2014 12 Actinium Pharmaceuticals, Inc. - Phase I, 2014 13 Actinium Pharmaceuticals, Inc. - Preclinical, 2014 14 Actinium Pharmaceuticals, Inc. - Pipeline by Target, 2014 25 Actinium Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 26 Actinium Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 27 Actinium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 28 Actinium Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 29 Actinium Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 34 Actinium Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 35
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.